Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Bousquet

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Bioorganic & Medicinal Chemistry Letters|June 6, 2006
Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitorsJürgen Dinges, Irini Akritopoulou-Zanze, Lee D Arnold, et al.
Bioorganic & Medicinal Chemistry Letters|June 1, 2006
Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinasesZhiqin Ji, Asma A Ahmed, Daniel H Albert, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2004
Isoindolinone ureas: a novel class of KDR kinase inhibitorsMichael L Curtin, Robin R Frey, H Robin Heyman, et al.
Bioorganic & Medicinal Chemistry Letters|June 9, 2006
1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitorsJürgen Dinges, Kimba L Ashworth, Irini Akritopoulou-Zanze, et al.
Journal of Medicinal Chemistry|February 12, 2008
3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinasesZhiqin Ji, Asma A Ahmed, Daniel H Albert, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2006
Thienopyridine urea inhibitors of KDR kinaseH Robin Heyman, Robin R Frey, Peter F Bousquet, et al.
Molecular Cancer Therapeutics|May 2, 2006
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitorDaniel H Albert, Paul Tapang, Terrance J Magoc, et al.
Journal of Medicinal Chemistry|September 16, 2005
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitorsYujia Dai, Yan Guo, Robin R Frey, et al.
Journal of Medicinal Chemistry|April 12, 2007
1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channelJürgen Dinges, Daniel H Albert, Lee D Arnold, et al.
Journal of Medicinal Chemistry|March 9, 2007
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitorYujia Dai, Kresna Hartandi, Zhiqin Ji, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Bioorganic & Medicinal Chemistry Letters|June 6, 2006
Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitorsJürgen Dinges, Irini Akritopoulou-Zanze, Lee D Arnold, et al.
Bioorganic & Medicinal Chemistry Letters|June 1, 2006
Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinasesZhiqin Ji, Asma A Ahmed, Daniel H Albert, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2004
Isoindolinone ureas: a novel class of KDR kinase inhibitorsMichael L Curtin, Robin R Frey, H Robin Heyman, et al.
Bioorganic & Medicinal Chemistry Letters|June 9, 2006
1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitorsJürgen Dinges, Kimba L Ashworth, Irini Akritopoulou-Zanze, et al.
Journal of Medicinal Chemistry|February 12, 2008
3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinasesZhiqin Ji, Asma A Ahmed, Daniel H Albert, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2006
Thienopyridine urea inhibitors of KDR kinaseH Robin Heyman, Robin R Frey, Peter F Bousquet, et al.
Molecular Cancer Therapeutics|May 2, 2006
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitorDaniel H Albert, Paul Tapang, Terrance J Magoc, et al.
Journal of Medicinal Chemistry|September 16, 2005
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitorsYujia Dai, Yan Guo, Robin R Frey, et al.
Journal of Medicinal Chemistry|April 12, 2007
1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channelJürgen Dinges, Daniel H Albert, Lee D Arnold, et al.
Journal of Medicinal Chemistry|March 9, 2007
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitorYujia Dai, Kresna Hartandi, Zhiqin Ji, et al.
Pageof 8